Neratinib plus fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial Meeting Abstract

  

Authors:	Hyman, D.; Piha-Paul, S.; Saura, C.; Arteaga, C.; Mayer, I.; Shapiro, G.; Loi, S.; Lalani, A.; Xu, F.; Cutler, R.; Butturini, A.; Bryce, R.; Meric-Bernstam, F.; Baselga, J.; Solit, D.
Abstract Title:	Neratinib plus fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial
Meeting Title:	2016 San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	77
Issue:	4 Suppl.
Meeting Dates:	2016 Dec 6-10
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2017-02-01
Language:	English
ACCESSION:	WOS:000397999002361
DOI:	10.1158/1538-7445.sabcs16-pd2-08
PROVIDER:	wos
Notes:	Meeting Abstract: PD2-08 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/109949